Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 14/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 14/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27088356 | 0.78 | KEAP1 (0.62) | KEAP1NFE2L2MAPTNPC1RAB9A | |
| SCHEMBL21286181 | 0.76 | KDR (0.45) | KEAP1NFE2L2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27088365 | 0.76 | TEK (0.45) | MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL22050888 | 0.76 | CHRNB2 (0.46) | MAPT | |
| SCHEMBL25820297 | 0.76 | CYP19A1 (0.51) | — | |
| SCHEMBL27984026 | 0.75 | MEN1 (0.61) | KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL19449446 | 0.74 | CHRNB2 (0.51) | KEAP1NFE2L2MAPTNPC1RAB9A | |
| SCHEMBL9963176 | 0.74 | CYP19A1 (0.66) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13225999 | 0.73 | KEAP1 (0.50) | KEAP1NFE2L2MAPTNPC1RAB9A | |
| SCHEMBL16515657 | 0.73 | ALDH1A1 (0.54) | KEAP1NFE2L2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2024-10-03 | — | — | US | disclosed |
| EP-4320109-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | Tolremo Therapeutics AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| CN-117355512-A | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | 托雷莫治疗股份公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022214606-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, MAPT, SLC6A6 | KEAP1 1383/4885NFE2L2 1030/4885MAPT 2/4885 |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | KEAP1 1166/4885NFE2L2 1385/4885MAPT 2/4885 |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | KEAP1 1166/4885NFE2L2 1385/4885MAPT 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.